Press Releases
Sanders, Cummings Send Letter on ARIAD's Staggering Drug Price Increases
WASHINGTON, Oct. 20 — Sen. Bernie Sanders (I-Vt.) and Rep. Elijah Cummings (D-Md.) sent a letter to ARIAD Pharmaceuticals, Inc. Thursday requesting information about why the company has increased the price of leukemia drug Iclusig four times in 2016 to $199,000 a year.
Cummings Releases Backgrounder on Latest Republican Allegations about Secretary Clinton's Emails
Republicans have once again omitted key information in their obsession with Secretary Clinton's emails in an attempt to impact the election.
This time, Republicans claim that an FBI official proposed a "quid pro quo" in which the FBI would downgrade its classification of one of Secretary Clinton's emails if State Department Under Secretary Patrick Kennedy supported allowing more FBI personnel into Iraq.
Top House Dems Call for FBI Action on Trump Campaign's Advance Knowledge of Ongoing Russian Cyber Hacking to Affect Election
Washington, D.C. (Oct. 14, 2016)—Today, Reps. Elijah E. Cummings, John Conyers, Jr., Elliot L. Engel, and Bennie G.
Chaffetz, Cummings Request Further Details on EpiPen ProfitsLetter requests detailed financial information on sales, profits, costs, etc. |
House Republicans Issued More Than 70 Subpoenas and Letters Investigating Hillary Clinton Just Since the FBI's Decision on Emails in July
"Desperate Onslaught of Frivolous Attacks"
Cummings, Brady, and Clyburn Call on EAC Executive Director to Rescind Unilateral Action
Newby Failed to Weigh Potential for Voter Disenfranchisement
Cummings Issues Statement on Inaccurate Republican Leaks About Limited Immunity Agreement with Cheryl Mills
Washington, DC (Sept. 23, 2016)—Today, Rep. Elijah E. Cummings, Ranking Member of the House Committee on Oversight and Government Reform, issued the following statement in response to inaccurate Republican leaks regarding a limited immunity agreement for Cheryl Mills:
All Democrats on Oversight and Ways and Means Committees Warn Judiciary Committee:
Do Not Promote Baseless Accusations Against IRS Commissioner
Ranking Members Release New Letters with IRS Inspector General
Oversight Committee to Hold Hearing on EpiPen Price Increases
Washington, D.C. (Sept. 14, 2016)—On Wednesday, September 21, 2016, the House Committee on Oversight and Government Reform will hold a bipartisan hearing with officials from Mylan, which dramatically increased its prices for EpiPens.